THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) and (f) The alleged over-invoicing of imports of drugs by various drug companies including that of M/s. German Remedies were referred to Enforcement Directorate for inquiry and investigation. After detailed investigation, the Enforcement Directorate has conveyed that their investigation do not disclose contravention of the various provisions of FERA Act, 1973. To the extent information is available, Nitroso Compound is not imported by the Company.

(d) Mr. Gordon R. Wing.

(e) No, Sir. There is absolutely no basis for such a charge against the Officer concerned.

Increase in drug prices

3595. SHRI ANANT RAM JAISWAL:
SHRI H. HANUMANTHAPPA:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 512 given in the Rajya Sabha on the 26th November, 1992 and state;

(a) what are the names of drugs where his Ministry have allowed increases on suo moto basis during the last three years, yearwise;

(b) what are the names of the producers and what was the production of each during the same period;

(c) what are the names of main intermediates required for each drug and what was the CIF price of each available at the time of suo moto increase in the respective drug and what was the consumption norm taken in each case;

(d) whether his Ministry have called the details of stocks of intermediates and the respective drug from any of the producer;

(e) if so, the names of such producers; and

(f) what are the names/composition of formulations based on these drugs whose prices were increased suo moto and what was its earlier and increased price of each?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN) (a) and (b) Price increases have been allowed and notified in respect of a number of bulk drugs during the last 3 years, as per the provisions of DPCO, 1987 from time to time, copies of which are available in the Parliament House Library. However, prices of 55 bulk drugs using imported raw materials were revised by the Government in 1991 due to change in exchange rate of rupee against major foreign currencies on the basis of cost data available with the Government and in consultation with BACP as per provisions of DPCO, 1987. The names of bulk drugs are given in the enclosed statement (see below). As per the provisions of DPCO, 1987 the price of bulk drugs are fixed drugwise and not producerwise.

(c) to (c) The prices of 55 bulk drugs using imported raw materials were revised by the Government after taking into account the total imported inputs including intermediates and raw materials which differ from drug to drug and manufacturer to manufacturer, depending upon the stages of production and technology etc., whose numbers would run into several thousands and time and labour involved in compiling this information will not be commensurate with results likely to be achieved.

(f) The prices of ceiling packs of formulations based on 55 bulk drugs referred to above were also revised on suo-moto basis. These prices were notified in the Official Gazette, a copy

of which is available in the Parliament House Library.

Statement

S.No.	Name of Bulk Drug
1.	Pyretal Pamoate
2.	Methyl Dopa
3.	Dextropropoxyphene Hel (To M/s Wockharot Ltd. only)
4.	Framycetin Sulphate
5.	Ibuprofen
6.	Chloroquine Phosphate
7.	Furazolidone
8.	Chloroquine Sulphate
9.	Mebhydroline Napadisylate
10.	Rifampicin
11.	Pyrazinamide
12.	Salbutamol Sulphate
13.	Sulphamoxole
14.	Insulin
15.	Cloxacillin (Sodium Oral Grade)
16.	Xylocaine/Lidocaine
17.	I.N.S. (Isoniazid)
18.	Cetrimide
19.	Ephedrine Hel
20.	Benzathine Penicillin. G
21.	Ethambutol
22.	Tarbutaline Sulphate
23.	Dexamethasone Pure
24.	Dexamethasone Phosphate
25.	Amodiaquine Hel
26.	Sulphadiazine
27.	Oxyfocin
28.	Diethylcarbamazine Citrate
29.	D.C.M.X.
30.	Sulphadimidine
31.	Levamisole Hel
32.	Dihydralazine Sulphate
33.	Iodochlorohydroxyquinoline
34.	Xanthibol Nic-otinate
35.	Gentamycin Sulphate
36.	Diloxanide Furoate
37.	Dimethyl Chlortetracycline
38.	Phenobarbitone
39.	Phenobarbitone Sodium
40.	Aminophyline
41.	Theophylline
42.	Hydroxyethyl Thephylline
43.	Oxytetracycline
44.	Sulphamethoxazole
45.	Tetracycline Hel
46.	Chlorhexidine Digloconate
47.	Spironolactone
48.	Para-chloro Meta-xylenol
49.	Cephalexin
50.	Frusemide
51.	Betamethasone Alcohol
52.	Betamethasone Valerate
53.	Bethamethasone Sodium Phophate
54.	Trimethoprim
55.	Ampicillin Anhydrous

Representation against exemption of Glybenclamide from price control

3596. SHRI SUDHIR RANJAN MAJUMDAR:
SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 526 given in Rajya Sabha on the 26th November, 1992 and state:

(a) whether it is a fact that his Ministry received a number of representations against the exemption of Glybenclamide from price control; and

(b) if so, what action has been taken on these representations?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) There were a number of representations in relation to several drugs, which, inter-alia included Glybenclamide also.

(b) The issues relating to inclusion/exclusion of drugs under price control have been intensively examined as part of the review of Drug Policy '86. The review excercise has taken into account, inter-alia, the need for evolving objective and transparent criteria for the purpose of selection of drugs for price control. The outline of the approach has been spelt out in a background note which has been placed on the Tables of both the Houses of Parliament on 12th August,